 Connection
Peter Anderson to Clinical Trials as Topic
This is a "connection" page, showing publications Peter Anderson has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.292 |
|
|
|
-
Marlow N, Doyle LW, Anderson P, Johnson S, Bhatt-Mehta V, Natalucci G, Darlow BA, Davis JM, Turner MA. Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants. Pediatr Res. 2019 11; 86(5):567-572.
Score: 0.109
-
Anderson PL, García-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2016 Jan; 11(1):94-101.
Score: 0.085
-
Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004 Nov; 38(11):1924-34.
Score: 0.039
-
Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin Pharmacol Ther. 2002 Apr; 71(4):280-5.
Score: 0.033
-
Lenaerts E, Matheï C, Matthys F, Zeeuws D, Pas L, Anderson P, Aertgeerts B. Continuing care for patients with alcohol use disorders: a systematic review. Drug Alcohol Depend. 2014 Feb 01; 135:9-21.
Score: 0.018
-
Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000 Jun; 30 Suppl 2:S151-9.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|